Prostate Cancer - Results from #40

Evaluating CRPC Definition: Comparing Upfront ARSI and Conventional Hormonal Therapy for Metastatic Hormone Sensitive Prostate Cancer (mHSPC) in Real World Propensity Score Matched Cohort. April 10, 2025

Pelvic Lymph Node Dissection in Prostate Cancer: Evidence and Implications. April 10, 2025

Making prostate cancer research accessible: chatGPT-4 as a tool to enhance lay communication. April 10, 2025

Validation and Derivation of MicroRNA-based Germline Signatures Predicting Radiation Toxicity in Prostate Cancer. April 10, 2025

A Large-scale Digital Survey of Patients with Localized and Advanced Prostate Cancer in Germany, the UK, and the USA. April 10, 2025

Diagnostic Accuracy of Combination of Multiparametric MRI PI-RADS Score v2.1 and Prostate-Specific Antigen Density for Prostate Cancer Detection. April 9, 2025

Fast prostate MRI vs. conventional multiparametric prostate MRI: comparison and outcomes. April 9, 2025

The association between statin use, genetic variation, and prostate cancer risk. April 9, 2025

Mind matters: how anxiety and depression shape low-risk prostate cancer active surveillance adherence in a real-world population. April 9, 2025

Cancer-control outcomes of Radium- 223-pretreated lutetium- 177-PSMA Radioligand vs. Radium- 223-naïve mCRPC patients. April 9, 2025

Urologists' Estimation of Online Support Group Utilization Behavior of Their Patients With Newly Diagnosed Nonmetastatic Prostate Cancer in Germany: Predefined Secondary Analysis of a Randomized Controlled Trial. April 9, 2025

Accuracy is Key: Transrectal Ultrasound Versus Magnetic Resonance Imaging to Determine Prostatic Volume. April 8, 2025

Men's experiences of the Swedish Organised Prostate Cancer Testing programme: a qualitative study. April 8, 2025

SpaceOAR hydrogel complications in prostate cancer radiotherapy: a pictorial review. April 8, 2025

First-line talazoparib plus enzalutamide versus placebo plus enzalutamide in men with metastatic castration-resistant prostate cancer and homologous recombination repair gene alterations: patient-reported outcomes from the randomised, double-blind, placeb April 8, 2025

First-line talazoparib plus enzalutamide versus placebo plus enzalutamide for metastatic castration-resistant prostate cancer: patient-reported outcomes from the randomised, double-blind, placebo-controlled, phase 3 TALAPRO-2 trial. April 8, 2025

Study of persistence and adherence to ADT in prostate cancer: relugolix, degarelix, and GnRH agonists in the US. April 8, 2025

New Study Published in Clinical Cancer Research Validates PROSTOX ultra Diagnostic Test for Predicting Radiation-Induced Late Toxicity in Prostate Cancer April 7, 2025

Validation and Derivation of MicroRNA-based Germline Signatures Predicting Radiation Toxicity in Prostate Cancer April 7, 2025

Real-world utilization patterns and survival in men with metastatic prostate cancer treated with Radium-223 in the United States. April 7, 2025

Page 3 of 1472